Arepanrix clinical trials
How each study uses arepanrix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Arepanrix
- 5
Studies by the year they started
5 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
GlaxoSmithKline (2) · Canadian Immunization Research Network (1) · University of British Columbia (1) · David Scheifele (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test arepanrix.
- Feb 2027Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartPhase 4 · Canadian Immunization Research Network
Studies
Open first, then newest update. How each study uses arepanrix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartActive, not recruitingPhase 4Canadian Immunization Research NetworkNCT07275060Written as H5N1 vaccine (Arepanrix)
- Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of AgeCompletedPhase 3GlaxoSmithKlineNCT01051661Written as GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
- Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or OlderCompletedPhase 4GlaxoSmithKlineNCT01114620Written as Arepanrix™
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIVCompletedPhase 4University of British ColumbiaNCT01002040Written as Arepanrix
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and AdultsCompletedPhase 4David ScheifeleNCT01001026Written as Arepanrix